Global to push GA events into
skip to main content

Title: Peptides having reduced toxicity that stimulate cholesterol efflux

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.
Inventors:
; ;
Issue Date:
OSTI Identifier:
1298004
Assignee:
The Regents of the University of California (Oakland, CA) LBNL
Patent Number(s):
9,416,162
Application Number:
14/216,749
Contract Number:
AC02-05CH11231
Resource Relation:
Patent File Date: 2014 Mar 17
Research Org:
Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES

Works referenced in this record:

Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat
journal, November 2002

Characteristics of the amino acids as components of a peptide hormone sequence
book, January 1976

Effects of l- or d-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic α-helical model peptide on structure and cell selectivity
journal, February 2004
  • Song, Yun Mi; Yang, Sung-Tae; Lim, Shin Saeng
  • Biochemical and Biophysical Research Communications, Vol. 314, Issue 2, p. 615-621
  • DOI: 10.1016/j.bbrc.2003.12.142